Cipla Q2 Review - In-Line, Next Set Of Key Launches In The U.S. In H2 FY23: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Cipla Ltd.’s Q2 was in-line with estimates across as Covid-19 sales in India moderated while gAlbuterol in the U.S. maintained its market share.
While near-term erosion in the base could be mitigated by further gains in gAlbuterol and contribution from gBrovana, U.S. revenue (quarterly run rate of ~$140 million) is unlikely to surprise on the upside in the absence of near-term catalysts with Cipla’s U.S. inhalation and complex generic pipeline (gRevlimid, gAbraxane and gAdvair) expected to start contributing meaningfully only from H2 FY23.
The reversion to normalised growth rates in the core domestic business and the absence of a meaningful recovery in other markets could render the current elevated margin levels unsustainable going forward.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.